AuthorsFlotte, Terence R.
UMass Chan AffiliationsDepartment of Pediatrics
KeywordsCongenital, Hereditary, and Neonatal Diseases and Abnormalities
Genetics and Genomics
Respiratory Tract Diseases
MetadataShow full item record
AbstractEfforts to develop gene therapies for cystic fibrosis (CF) helped to drive vector innovations more than two decades ago, including the first use of recombinant adenovirus (rAd) and recombinant adeno-associated virus (rAAV) for in vivo gene therapy and for human use. These early-generation vectors failed to progress in clinical trials, however, because of immune responses and the failure of these episomal vectors to result in stable transduction of the airway progenitor cells, particularly basal cells in the conducting airways. Two articles in the current issue of Human Gene Therapy address this issue directly by using newer vector systems: helper-dependent adenovirus (HD-Ad) and lentivirus (LV) vectors.
Hum Gene Ther. 2018 Jun;29(6):641-642. doi: 10.1089/hum.2018.29066.trf. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/43654